The BOOS 2019 Committee are delighted to be partnered with the following:
implantcast GmbH, founded in 1988 is one of the leading specialists in its sector regarding development, construction and production of joint replacements. Our core competence lies in the manufacture of endoprostheses as functional joint replacements, specialist implants and customized products. Constant investment in our manufacturing plant, highest quality German manufacturing tolerances, qualified employees and its specialized services are the fundamental pillars of our company’s success.
Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. Together with our customers, we are driven to make healthcare better. Our products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, neurovascular, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. The consistent theme running through all of Stryker’s business is that of improving clinical outcomes for patients. This can only be achieved by partnering with the medical community, working with and listening to our customers and their patients, their needs and visions. Helping millions of people lead more active and satisfying lives.
Adler UK is a subsidiary of Adler Ortho SpA, a privately owned Italian company, focused on innovative technology and specialising in the design, manufacture, marketing of orthopaedic implants. Adler was the first orthopaedic company to employ additive layer manufacturing (ALM) technology in orthopaedics, allowing production of complex 3D shapes, providing an ideal porous structure enhancing biological integration. We print using both Ti and CoCr alloys. Alongside the widest portfolio of ALM primary implants made with Tri-Por®, Adler also offer a responsive, full custom products service, with over 10 years experience for oncological, trauma and revision indications. Utilising the advantages of ALM, Adler is fully focused on enhancing outcomes for limb salvage surgery; improving long term fixation and enhancing implant function. In the war against peri-prosthetic infection, DAC anti-infective hydrogel provides proven prevention of biofilm, allowing surgeons to pre-coat the device with their choice of antibiotic for maximum targeted protection.
With over 70 years in Orthopedics, LINK has pioneered developments in joint replacement for primary and revision hip, knee and tumor surgery.
Our responsibility is to only sell implants we would be willing to have implanted in ourselves. The current LINK product range includes leading legacy implants with documented and reproducible results, such as the Endo-Model rotating hinge knee, MP revision stems, Lubinus SPII anatomic hip and the Gemini total and Sled partial knee replacements. More recent innovations include the SP-CL anatomic cementless hip system and Megasystem-C complete tumor and revision system. Modern production facilities and German engineering, assure the famous LINK product quality known for the highest safety standards and best value for the patient.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.
As a non-profit organization, ETB-BISLIFE fulfils a mediating role aimed at the reliable acquisition and distribution of scarce human tissues for transplantation purposes in the Netherlands and Europe. The Foundation closely collaborates with many different care providers and care professionals, academic and peripheral hospitals, specialist tissue processors and other (international) tissue institutions and tissue banks, transplantation centres, laboratories and other organizations, not only in the Netherlands but also in Europe and beyond. Individual divisions work closely with physicians in the field and with patient associations optimizing the tissue chain, both nationally and internationally, and improving availability of scarce compatible tissues in the interest of patient wellbeing.